Published 5 days ago • loading... • Updated 1 day ago

Researchers warn cheaper knockoff weight-loss drugs may pose health risks

University of Mississippi researchers warn that compounded GLP-1 medications pose significant health risks as patients increasingly seek these custom-made alternatives due to rising costs and limited insurance coverage for FDA-approved options.
Insurance companies continue restricting coverage for popular FDA-approved drugs like Ozempic, Wegovy, and Zepbound, driving patients toward potentially unsafe compounded alternatives to manage obesity, which affects roughly 40% of American adults.
Sujith Ramachandran, a researcher at the University, warns that compounded versions often lack proper manufacturing oversight, meaning patients may unknowingly inject substances with unapproved ingredients instead of the intended medication.
The FDA has cautioned consumers about compounded products after finding unapproved ingredients in some formulations; researchers emphasize that long-term weight management requires ongoing medical support, nutrition counseling, and physical activity rather than medication alone.
Without continued treatment and lifestyle changes, many patients regain lost weight; researchers note that many stop taking medications within a year due to costs or side effects, complicating long-term weight management.

Insights by Ground AI